Product Description
BMF-650 is a next-generation, potent, selective, oral small-molecule GLP-1 receptor agonist (GLP-1 RA) under development by Biomea Fusion. (Sourced from: https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-host-conference-call-and-webcast-wednesday-october)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|